GlaxoSmithKline’s Nucala is facing an uphill climb in its battle for supremacy in severe asthma. On the hunt for a leg up, GSK is looking to real-world studies for a competitive advantage in Nucala’s sole indication—and it may have just scored one. After 12 months of use, Nucala cut severe eosinophilic asthma attacks by 69%… Read More »
Health in 2 Point 00 Sep 30, 2019• Today on Health in 2 Point 00, Jess and I catch up on loads of news in health tech. In this episode, Jess asks me about Amazon Care, doing telehealth, house calls, urgent care, drug delivery for their employees—could it change health delivery? Also, Echo raises $… Read More »
Women who suffer heart attacks are dying needlessly because they fail to recognise their symptoms and receive poorer care than men. says a British Heart Foundation report. Over 10 years, more than 8,000 women in England and Wales died unnecessarily after a heart attack, it found. Experts say there are inequalities in diagnosis, treatment and… Read More »
Print this page South San Francisco, CA — September 27, 2019 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in… Read More »